MedTrace Logo

A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics

NCT00973960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2011-08-08

No results posted yet for this study

Summary

The main objective of the study is to demonstrate the safety and efficacy of the EndoBarrier Flow Restrictor in the glycemic control of diabetes in subjects with Type 2 diabetes.

The primary efficacy endpoint is an assessment of glycemic control at week 24 or last assessment measured via HbA1c.

Conditions

Sponsors & Collaborators

  • Morphic Medical Inc.

    lead INDUSTRY

Principal Investigators

  • Alex Escalona, MD · Hospital Universidad Catolica

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-06-30
Completion
2010-12-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973960 on ClinicalTrials.gov